Platelet-cancer interactions: Mechanisms and pharmacology of tumour cell-induced platelet aggregation

British Journal of Pharmacology

Volumn 143, Issue 7, 2004, Pages 819-826

  Jurasz, Paul ^a   Alonso Escolano, David ^a   Radomski, Marek W ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

Cancer; Metastasis; Platelet aggregation; Tumour

Indexed keywords

ADENOSINE DIPHOSPHATE; ANTITHROMBOCYTIC AGENT; APYRASE; FIBRINOGEN RECEPTOR ANTAGONIST; METALLOPROTEINASE INHIBITOR; MOPIDAMOL; OZAGREL; PHENANTHROLINE; PHOSPHODIESTERASE INHIBITOR; THROMBOXANE; THROMBOXANE SYNTHASE INHIBITOR;

ANTINEOPLASTIC ACTIVITY; CELL INTERACTION; CELL STRAIN MCF 7; DRUG MECHANISM; ENZYME INHIBITION; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL; REVIEW; THROMBOCYTE; THROMBOCYTE AGGREGATION; THROMBOCYTE AGGREGATION INHIBITION; TUMOR CELL;

ANIMALS; ANTINEOPLASTIC AGENTS; BLOOD PLATELETS; HUMANS; NEOPLASMS; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS;

EID: 10844222440     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0706013     Document Type: Review

References (145)

1. ALONSO, D. & RADOMSKI, M.W. (2003). Nitric oxide, platelet function, myocardial infarction and reperfusion therapies. Heart Fail. Rev., 8, 47-54.
2. ALONSO-ESCOLANO, D., STRONGIN, A.Y., CHUNG, A.W., DERYUGINA, E.I. & RADOMSKI, M.W. (2004). Membrane type-1 matrix metalloproteinase stimulates tumour cell-induced platelet aggregation: role of receptor glycoproteins. Br. J. Pharmacol., 141, 241-252.
3. AMIRKHOSRAVI, A., MOUSA, S.A., AMAYA, M., BLAYDES, S., DESAI, H., MEYER, T. & FRANCIS, J.L. (2003). Inhibition of tumor cell-induced platelet aggregation and lung metastasis by the oral GpIIb/IIIa antagonist XV454. Thromb. Haemost., 90, 549-554.
4. BAKEWELL, S.J., NESTOR, P., PRASAD, S., TOMASSON, M.H., DOWLAND, N., MEHROTRA, M., SCARBOROUGH, R., KANTER, J., ABE, K., PHILLIPS, D. & WEILBAECHER, K.N. (2003). Platelet and osteoclast b3 integrins are critical for bone metastasis. Proc. Natl. Acad. Sci. U.S.A., 100, 14205-14210.
5. BANDO, H., YAMASHITA, T. & TSUBURA, E. (1984). Effects of antiplatelet agents on pulmonary metastases. Gann, 75, 284-291.
6. BASTIDA, E., ALMIRALL, L. & ORDINAS, A. (1987). Tumor-cell-induced platelet aggregation is a glycoprotein-dependent and lipoxygenase-associated process. Int. J. Cancer, 39, 760-763.
7. BASTIDA, E., ESCOLAR, G., ALMIRALL, L. & ORDINAS, A. (1986a). Platelet activation induced by a human neuroblastoma tumor cell line is reduced by prior administration of ticlopidine. Thromb. Haemost., 55, 333-337.
8. BASTIDA, E., ESCOLAR, G., ORDINAS, A. & JAMIESON, G.A. (1986b). Morphometric evaluation of thrombogenesis by microvesicles from human tumor cell lines with thrombin-dependent (U87MG) and adenosine diphosphate-dependent (SKNMC) platelet-activating mechanisms. J. Lab. Clin. Med., 108, 622-627.
9. BAZZONI, G., DEJANA, E. & DEL-MASCHIO, A. (1991). Platelet-neutrophil interactions. Possible relevance in the pathogenesis of thrombosis and inflammation. Haematologica, 76, 491-499.
10. BLAHA, H., DIERKESMANN, R., FEUERER, W., GATZEMAIER, U., GESER, C., LEMME, J., MALL, W., RITSCHER, R., SCHNEIDER, B. & VALLEE, D. (1989). Adjuvant therapy of non-small cell bronchial cancer with mopidamol. Pneumologie, 43, 299-304.
11. BORN, G.V. (1966). Effects of adenosine diphosphate (ADP) and related substances on the adhesiveness of platelets in vitro and in vivo. Br. J. Haematol., 12, 37-38.
12. BOUKERCHE, H., BERTHIER-VERGNES, O., BAILLY, M., DORE, J.F., LEUNG, L.L. & MCGREGOR, J.L. (1989a). A monoclonal antibody (LYP18) directed against the blood platelet glycoprotein IIb/IIIa complex inhibits human melanoma growth in vivo. Blood, 74, 909-912.
13. BOUKERCHE, H., BERTHIER-VERGNES, O., PENIN, F., TABONE, E., LIZARD, G., BAILLY, M. & MCGREGOR, J.L. (1994). Human melanoma cell lines differ in their capacity to release ADP and aggregate platelets. Br. J. Haematol., 87, 763-772.
14. BOUKERCHE, H., BERTHIER-VERGNES, O., TABONE, E., DORE, J.F., LEUNG, L.L. & MCGREGOR, J.L. (1989b). Platelet-melanoma cell interaction is mediated by the glycoprotein Iib-IIIa complex. Blood, 74, 658-663.
15. BOZKURT, N., YUCE, K., BASARAN, M., KOSE, F. & AYHAN, A. (2004). Correlation of platelet count with second-look laparotomy results and disease progression in patients with advanced epithelial ovarian cancer. Obstet. Gynecol., 103, 82-85.
16. BRADLEY, C.J., DAUER, R.J., THURLOW, P.J. & CONNELLAN, J.M. (1997). Characterization of platelet aggregation induced by the human carcinosarcoma Colo 526: role of platelet activation, tumor cell cytoskeleton and tumor cell plasma membrane. Pathology, 29, 189-195.
17. CAINE, G.J., STONELAKE, P.S., REA, D. & LIP, G.Y. (2003). Coagulopathic complications in breast cancer. Cancer, 98, 1578-1586.
18. CELI, A., LORENZET, R., FURIE, B. & FURIE, B.C. (1997). Platelet-leukocyte-endothelial cell interaction on the blood vessel wall. Semin. Hematol., 34, 327-335.
19. CHOPRA, H., HATFIELD, J.S., CHANG, Y.S., GROSSI, I.M., FITZGERALD, L.A., O-GARA, C.Y., MARNETT, L.J., DIGLIO, C.A., TAYLOR, J.D. & HONN, K.V. (1988). Role of tumor cytoskeleton and membrane glycoprotein IRGpIIb/IIIa in platelet adhesion to tumor cell membrane and tumor cell-induced platelet aggregation. Cancer Res., 48, 3787-3800.
20. CHUNG, A.W., JURASZ, P., HOLLENBERG, M.D. & RADOMSKI, M.W. (2002). Mechanisms of action of proteinase-activated receptor agonists on human platelets. Br. J. Pharmacol., 135, 1123-1132.
21. CLEZARDIN, P., DROUIN, J., MOREL-KOPP, M.C., HANSS, M., KEHREL, B., SERRE, C.M., KAPLAN, C. & DELMAS, P.D. (1993). Role of platelet membrane glycoproteins Ib/IX and IIb/IIIa, and of platelet alpha-granule proteins in platelet aggregation induced by human osteosarcoma cells. Cancer Res., 53, 4695-4700.
22. COHEN, S.A., TRIKHA, M. & MASCELLI, M.A. (2000). Potential future clinical applications for the GPIIb/IIIa antagonist, abciximab in thrombosis, vascular and oncological indications. Pathol. Oncol. Res., 6, 163-174.
23. COSTANTINI, V., ZACHARSKI, L.R., MORITZ, T.E. & EDWARDS, R.L. (1990). The platelet count in carcinoma of the lung and colon. Thromb. Haemost., 64, 501-505.
24. COUGHLIN, S.R. (2000). Thrombin signalling and protease-activated receptors. Nature, 407, 258-264.
25. DE LEVAL, X., BENOIT, V., DELARGE, J., JULEMONT, F., MASEREEL, B., PIROTTE, B., MERVILLE, M.-P., DAVID, J.-L. & DOGNE, J.-M. (2003). Pharmacological evaluation of the novel thromboxane modulator BM-567 (II/II). Effects of BM-567 on osteogenic sarcoma-cell-induced platelet aggregation. Prostaglandins Leukot. Essent. Fatty Acids, 68, 55-59.
26. DONATI, M.B., GAMBACORTI-PASSERINI, C., CASALI, B., FALANGA, A., VANNOTI, P., FOSSATI, G., SEMERARO, N. & GORDON, S.G. (1986). Cancer procoagulant in human tumor cells: evidence from melanoma patients. Cancer Res., 46, 6471-6474.
27. ESUMI, N., TODO, S. & IMASHUKU, S. (1987). Platelet aggregating activity mediated by thrombin generation in the NCG human neuroblastoma cell line. Cancer Res., 47, 2129-2135.
28. FALANGA, A. & GORDON, S.G. (1985). Isolation and characterization of cancer procoagulant: a cysteine proteinase from malignant tissue. Biochemistry, 24, 5558-5567.
29. FELDING-HABERMANN, B., O-TOOLE, T.E., SMITH, J.W., FRANSVEA, E., RUGGERI, Z.M., GINSBERG, M.H., HUGHES, P.E., PAMPORI, N., SHATTIL, S.J., SAVEN, A. & MUELLER, B.M. (2001). Integrin activation controls metastasis in human breast cancer. Proc. Natl. Acad. Sci. U.S.A., 98, 1853-1858.
30. GASIC, G.J. (1984). Role of plasma, platelets, and endothelial cells in tumor metastasis. Cancer Metast. Rev., 3, 99-114.
31. GASIC, G.J., BOETTIGER, D., CATALFAMO, J.L., GASIC, T.B. & STEWART, G.J. (1978). Aggregation of platelets and cell membrane vesiculation by rat cells transformed in vitro by Rous sarcoma virus. Cancer Res., 38, 2950-2955.
32. GASIC, G.J., GASIC, T.B. & STEWART, C.C. (1968). Antimetastatic effects associated with platelet reduction. Proc. Natl. Acad. Sci. U.S.A., 61, 46-52.
33. GASIC, G.J., KOCH, P.A., HSU, B., GASIC, T.B. & NIEWIAROWSKI, S. (1976). Thrombogenic activity of mouse and human tumors: effects on platelets, coagulation, and fibrinolysis, and possible significance for metastases. Z. Krebsforsch. Klin. Onkol. Cancer Res. Clin. Oncol., 86, 263-277.
34. GINSBERG, M.H., LOFTUS, J. & PLOW, E.F. (1988). Platelets and the adhesion receptor superfamily. Prog. Clin. Biol. Res., 283, 171-195.
35. GINSBERG, M.H., XIAOPING, D., O'TOOLE, T.E., LOFTUS, J.C. & PLOW, E.F. (1993). Platelet integrins. Thromb. Haemost., 70, 87-93.
36. GOLIGORSKY, M.S., BUDZIKOWSKI, A.S., TSUKAHARA, H. & NOIRI, E. (1999). Co-operation between endothelin and nitric oxide in promoting endothelial cell migration and angiogenesis. Clin. Exp. Pharmacol. Physiol., 26, 269-271.
37. GRIGNANI, G., PACCHIARINI, L., ALMASIO, P., PAGLIARINO, M., GAMBA, G., RIZZO, S.C. & ASCARI, E. (1986). Characterization of the platelet-aggregating activity of cancer cells with different metastatic potential. Int. J. Cancer, 38, 237-244.
38. GRIGNANI, G., PACCHIARINI, L., RICETTI, M.M., DIONIGI, P., JEMOS, V., ZUCCHELLA, M. & FRATINO, P. (1989). Mechanisms of platelet activation by cultured human cancer cells and cells freshly isolated from tumor tissues. Invasion Metast., 9, 298-309.
39. GROSSI, I.M., HATFIELD, J.S., FITZGERALD, L.A., NEWCOMBE, M., TAYLOR, J.D. & HONN, K.V. (1988). Role of tumor cell glycoproteins immunologically related to glycoproteins Ib and IIb/IIIa in tumor cell-platelet and tumor cell-matrix interactions. FASEB J., 2, 2385-2395.
40. HAMILTON, J., SUBBARAO, V., GRANACK, K. & TSAO, C. (1986). Platelet interaction with a pancreatic ascites tumor. Am. J. Pathol., 122, 160-168.
41. HEFLER, L., MAYERHOFER, K., LEIBMAN, B., OBERMAIR, A., REINTHALLER, A., KAINZ, C. & TEMPFER, C. (2000). Tumor anemia and thrombocytosis in patients with vulvar cancer. Tumour Biol., 21, 309-314.
42. HEINMOLLER, E., SCHROPP, T., KISKER, O., SIMON, B., SEITZ, R. & WEINEL, R.J. (1995). Tumor cell-induced platelet aggregation in vitro by human pancreatic cancer cell lines. Scand. J. Gastroenterol., 30, 1008-1016.
43. HEINMOLLER, E., WEINEL, R.J., HEIDTMANN, H.H., SALGE, U., SEITZ, R., SCHMITZ, I., MULLER, K.M. & ZIRNGIBL, H. (1996). Studies on tumor-cell-induced platelet aggregation in human lung cancer cell lines. J. Cancer Res. Clin. Oncol., 122, 735-744.
44. HEJNA, M., RADERER, M. & ZIELINSKI, C.C. (1999). Inhibition of metastases by anticoagulants. J. Natl. Cancer Inst., 91, 22-36.
45. HERNANDEZ, E., LAVINE, M., DUNTON, C.J., GRACELY, E. & PARKER, J. (1992). Poor prognosis associated with thrombocytosis in patients with cervical cancer. Cancer, 69, 2975-2977.
46. HONN, K.V., BOCKMAN, R.S. & MARNETT, L.J. (1981a). Prostaglandins and cancer: a review of tumor initiation through tumor metastasis. Prostaglandins, 21, 833-864.
47. HONN, K.V., CAVANAUGH, P., EVENS, C., TAYLOR, J.D. & SLOANE, B.F. (1982). Tumor cell-platelet aggregation: induced by cathepsin B-like proteinase and inhibited by prostacyclin. Science, 217, 540-542.
48. HONN, K.V., CHEN, Y.Q., TIMAR, J., ONODA, J.M., HATFIELD, J.S., FLIGIEL, S.E., STEINERT, B.W., DIGLIO, C.A., GROSSI, I.M. & NELSON, K.K. (1992a). Alpha IIb beta 3 integrin expression and function in subpopulations of murine tumors. Exp. Cell Res., 201, 23-32.
49. HONN, K.V., CICONE, B. & SKOFF, A. (1981b). Prostacyclin: a potent antimetastatic agent. Science, 212, 1270-1272.
50. HONN, K.V. & MEYER, J. (1981). Thromboxanes and prostacyclin: positive and negative modulators of tumor growth. Biochem. Biophys. Res. Commun., 102, 1122-1129.
51. HONN, K.V. & TANG, D. (1992). Hemostasis and malignancy: an overview. Cancer Metast. Rev., 11, 223-226.
52. HONN, K.V., TANG, D.G. & CHEN, Y.Q. (1992b). Platelets and cancer metastasis: more than an epiphenomenon. Semin. Thromb. Hemost., 18, 392-415.
53. IKEDA, M., FURUKAWA, H., IMAMURA, H., SHIMIZU, J., ISHIDA, H., MASUTANI, S., TATSUTA, M. & SATOMI, T. (2002). Poor prognosis associated with thrombocytosis in patients with gastric cancer. Ann. Surg. Oncol., 9, 287-291.
54. IWAMURA, T., CAFFREY, T.C., KITAMURA, N., YAMANARI, H., SETOGUCHI, T. & HOLLINGSWORTH, M.A. (1997). P-selectin expression in a metastatic pancreatic tumor cell line (SUIT-2). Cancer Res., 57, 1206-1212.
55. JENKINS, D.C., CHARLES, I.G., BAYLIS, S.A., LELCHUK, R., RADOMSKI, M.W. & MONCADA, S. (1994). Human colon cancer cell lines show a diverse pattern of nitric oxide synthase gene expression and nitric oxide generation. Br. J. Cancer, 70, 847-849.
56. JURASZ, P., ALONSO, D., CASTRO-BLANCO, S., MURAD, F. & RADOMSKI, M.W. (2003a). Generation and role of angiostatin in human platelets. Blood, 102, 3217-3223.
57. JURASZ, P., CHUNG, A.W., RADOMSKI, A. & RADOMSKI, M.W. (2002). Nonremodeling properties of matrix metalloproteinases: the platelet connection. Circ. Res., 90, 1041-1043.
58. JURASZ, P., NORTH, S., VENNER, P. & RADOMSKI, M.W. (2003b). Matrix metalloproteinase-2 contributes to increased platelet reactivity in patients with metastatic prostate cancer: a preliminary study. Thromb. Res., 112, 59-64.
59. JURASZ, P., RADOMSKI, A., SAWICKI, G., MAYERS, I. & RADOMSKI, M.W. (2000). Nitric oxide and platelet function. In: Nitric Oxide Biology and Pathobiology, ed Ignarro, L.J. San Diego/San Francisco/New York/Boston/Sydney/ Tokyo: Academic Press, pp. 823-840.
60. JURASZ, P., SAWICKI, G., DUSZYK, M., SAWICKA, J., MIRANDA, C., MAYERS, I. & RADOMSKI, M.W. (2001a). Matrix metalloproteinase 2 in tumor cell-induced platelet aggregation: regulation by nitric oxide. Cancer Res., 61, 376-382.
61. JURASZ, P., STEWART, M.W., RADOMSKI, A., KHADOUR, F., DUSZYK, M. & RADOMSKI, M.W. (2001b). Role of von Willebrand factor in tumour cell-induced platelet aggregation: differential regulation by NO and prostacyclin. Br. J. Pharmacol., 134, 1104-1112.
62. KAHN, M.L., NAKANISHI-MATSUI, M., SHAPIRO, M.J., ISHIHARA, H. & COUGHLIN, S.R. (1999). Protease-activated receptors 1 and 4 mediate activation of human platelets by thrombin. J. Clin. Invest., 103, 879-887.
63. KAKKAR, A.K. (2003a). Antithrombotics and cancer: evidence for survival benefit. Pathophysiol. Haemost. Thromb., 33, 67.
64. KAKKAR, A.K. (2003b). Low-molecular-weight heparins: Beyond thrombosis in the management of the cancer patient. Semin. Thromb. Hemost., 29, 13-15.
65. KARPATKIN, S., PEARLSTEIN, E., AMBROGIO, C. & COLLER, B.S. (1988). Role of adhesive proteins in platelet tumor interaction in vitro and metastasis formation in vivo. J. Clin. Invest., 81, 1012-1019.
66. KARPATKIN, S., PEARLSTEIN, E., SALK, P.L. & YOGEESWARAN, G. (1981). Role of platelets in tumor cell metastases. Ann. N. Y. Acad. Sci., 370, 101-118.
67. KERPSACK, J.T. & FINAN, M.A. (2000). Thrombocytosis as a predictor of malignancy in women with a pelvic mass. J. Reprod. Med., 45, 929-932.
68. KIM, Y.J., BORSIG, L., HAN, H.-L., VARKI, N.M. & VARKI, A. (1999). Distinct selectin ligands on colon carcinoma mucins can mediate pathological interactions among platelets, leukocytes, and endothelium. Am. J. Pathol., 155, 461-472.
69. KIM, Y.J., BORSIG, L., VARKl, N.M. & VARKI, A. (1998). P-selectin deficiency attenuates tumor growth and metastasis. Proc. Natl. Acad. Sci. U.S.A., 95, 9325-9330.
70. KWAAN, H.C. & KEER, H.N. (1990). Fibrinolysis and cancer. Semin. Thromb. Hemost., 16, 230-235.
71. LARSEN, E., CELI, A., GILBERT, G.E., FURIE, B.C., ERBAN, J.K., BONFANTI, R., WAGNER, D.D. & FURIE, B. (1989). PADGEM protein: a receptor that mediates the interaction of activated platelets with neutrophils and monocytes. Cell, 59, 305-312.
72. LEBEAU, B., CHASTANG, C, MUIR, J.F., VINCENT, J., MASSIN, F. & FABRE, C. (1993). No effect of an antiaggregant treatment with aspirin in small cell lung cancer treated with CCAVP16 chemotherapy. Results from a randomized clinical trial of 303 patients. The 'Petites Cellules' Group. Cancer, 71, 1741-1745.
73. LEE, A.Y. & LEVINE, M.N. (2003). Venous thromboembolism and cancer: risks and outcomes. Circulation, 107, 117-21.
74. LEE, A.Y., LEVINE, M.N., BAKER, R.I., BOWDEN, C., KAKKAR, A.K., PRINS, M., RICKLES, F.R., JULIAN, J.A., HALEY, S., KOVACS, M.J. & GENT, M. (2003a). Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N. Engl. J. Med., 349, 146-153.
75. LEE, A.Y.Y., LEVINE, M.N., BAKER, R.I., BOWDEN, C., KAKKAR, A.K., PRINS, M., RICKLES, F.R., JULIAN, J.A., HALEY, S., KOVACS, M.J., GENT, M. & The randomized comparison of low-molecular-weight heparin versus oral anticoagulant therapy for the prevention of recurrent venous thromboembolism in patients with cancer (CLOT) investigators (2003b). Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N. Engl. J. Med., 349, 146-153.
76. LEPOIVRE, M., FIESCHI, F., COVES, J., THELANDER, L. & FONTECAVE, M. (1991). Inactivation of ribonucleotide reductase by nitric oxide. Biochem. Biophys. Res. Commun., 179, 442-448.
77. LERNER, W.A., PEARLSTEIN, E., AMBROGIO, C. & KARPATKIN, S. (1983). A new mechanism for tumor induced platelet aggregation. Comparison with mechanisms shared by other tumor with possible pharmacologic strategy toward prevention of metastases. Int. J. Cancer, 31, 463-469.
78. LEVINE, M.N. & LEE, A.Y.Y. (2001). Treatment of venous thrombosis in the cancer patient. Acta Haematol., 106, 81-87.
79. LIPTON, A., SCIALLA, S., HARVEY, H., DIXON, R., GORDON, R., HAMILTON, R., RAMSEY, H., WELTZ, M., HECKARD, R. & WHITE, D. (1982). Adjuvant antiplatelet therapy with aspirin in colo-rectal cancer. J. Med., 13, 419-429.
80. LONGENECKER, G.L., BEYERS, B.J., BOWEN, R.J. & KING, T. (1989). Human rhabdosarcoma cell-induced aggregation of blood platelets. Cancer Res., 49, 16-19.
81. LOPES, A., DARAS, V., CROSS, P.A., ROBERTSON, G., BEYNON, G. & MONAGHAN, J.M. (1994). Thrombocytosis as a prognostic factor in women with cervical cancer. Cancer, 74, 90-92.
82. LORETO, M.F., DE-MARTINIS, M., CORSI, M.P., MODESTI, M. & GINALDI, L. (2000). Coagulation and cancer: implications for diagnosis and management. Pathol. Oncol. Res., 6, 301-312.
83. MALIK, A.B. (1983). Pulmonary microembolism. Physiol. Rev., 63, 1114-1207.
84. MANEGOLD, P.C., HUTTER, J., PAHERNIK, S.A., MESSMER, K. & DELLIAN, M. (2003). Platelet-endothelial interaction in tumor angiogenesis and microcirculation. Blood, 101, 1970-1976.
85. MARAGOUDAKIS, M.E., TSOPANOGLOU, N.E., ANDRIOPOULOU, P. & MARAGOUDAKIS, M.-E.M. (2000). Effects of thrombin/ thrombosis in angiogenesis and tumour progression. Matrix Biol., 19, 345-351.
86. MEHTA, P., LAWSON, D., WARD, M.B., LEE-AMBROSE, L. & KIMURA, A. (1986). Effects of thromboxane A2 inhibition on osteogenic sarcoma cell-induced platelet aggregation. Cancer Res., 46, 5061-5063.
87. MENCZER, J., SCHEJTER, E., GEVA, D., GINATH, S. & ZAKUT, H. (1998). Ovarian carcinoma associated thrombocytosis. Correlation with prognostic factors and with survival. Eur. J. Gynaecol. Oncol., 19, 82-84.
88. MENTER, D.G., HARKINS, C., ONODA, J., RIORDEN, W., SLOANE, B.F., TAYLOR, J.D. & HONN, K.V. (1987a). Inhibition of tumor cell induced platelet aggregation by prostacyclin and carbacyclin: an ultrastructural study. Invasion Metast., 1, 109-128.
89. MENTER, D.G., ONODA, J.M., MOILANEN, D., SLOANE, B.F., TAYLOR, J.D. & HONN, K.V. (1987b). Inhibition by prostacyclin of the tumor cell-induced platelet release reaction and platelet aggregation. J. Natl. Cancer Inst., 78, 961-969.
90. MENTER, D.G., ONODA, J.M., TAYLOR, J.D. & HONN, K.V. (1984). Effects of prostacyclin on tumor cell-induced platelet aggregation. Cancer Res., 44, 450-456.
91. MONCADA, S., GRYGLEWSKI, R., BUNTING, S. & VANE, J.R. (1976). An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature, 263, 663-665.
92. MOORE, K.L. (1998). Structure and function of P-selectin glycoprotein ligand-1. Leuk. Lymphoma, 29, 1-15.
93. NAKANO, T., FUJII, J., TAMURA, S., HADA, T. & HIGASHINO, K. (1986). Thrombocytosis in patients with malignant pleural mesothelioma. Cancer, 58, 1699-1701.
94. NEEDLEMAN, P., MONCADA, S., BUNTING, S., VANE, J.R., HAMBERG, M. & SAMUELSSON, B. (1976). Identification of an enzyme in platelet microsomes which generates thromboxane A2 from prostaglandin endoperoxides. Nature, 261, 558-560.
95. O'KEEFE, S.C., MARSHALL, F.F., ISSA, M.M., HARMON, M.P. & PETROS, J.A. (2002). Thrombocytosis is associated with a significant increase in the cancer specific death rate after radical nephrectomy. J. Urol., 168, 1378-1380.
96. OLAS, B., WACHOWICZ, B., MIELICKI, W.P. & BUCZYNSKI, A. (2000). Free radicals are involved in cancer procoagulant-induced platelet activation. Thromb. Res., 97, 169-175.
97. OLEKSOWICZ, L. & DUTCHER, J.P. (1995). Adhesive receptors expressed by tumor cells and platelets: novel targets for therapeutic anti-metastatic strategies. Med. Oncol., 12, 95-102.
98. OLEKSOWICZ, L., MROWIEC, Z., SCHWARTZ, E., KHORSHIDI, M., DUTCHER, J.P. & PUSZKIN, E. (1995). Characterization of tumor-induced platelet aggregation: the role of immunorelated GPIb and GPIIb/IIIa expression by MCF-7 breast cancer cells. Thromb. Res., 79, 261-274.
99. OLESEN, L.L. & THORSHAUGE, H. (1988). Thrombocytosis in patients with malignant pleural mesothelioma. Cancer, 62, 1194-1196.
100. OVERALL, C.M. & LOPEZ-OTIN, C. (2002). Strategies for MMP inhibition in cancer: innovations for the post-trial era. Nat. Rev. Cancer, 2, 657-672.
101. PACCHIARINI, L., ZUCCHELLA, M., MILANESI, G., TACCONI, F., BONOMI, E., CANEVARI, A. & GRIGNANI, G. (1991). Thromboxane production by platelets during tumor cell-induced platelet activation. Invasion Metast., 11, 102-109.
102. PALMER, R.M., ASHTON, D.S. & MONCADA, S. (1988). Vascular endothelial cells synthesize nitric oxide from L-arginine. Nature, 333, 664-666.
103. PEARLSTEIN, E., AMBROGIO, C., GASIC, G. & KARPATKIN, S. (1981). Inhibition of the platelet-aggregating activity of two human adenocarcinomas of the colon and an anaplastic murine tumor with a specific thrombin inhibitor, dansylarginine N-(3-ethyl-1,5-pentanediyl)amide. Cancer Res., 41, 4535-4539.
104. PEDERSEN, L.M. & MILMAN, N. (1996). Prognostic significance of thrombocytosis in patients with primary lung cancer. Eur. Respir. J., 9, 1826-1830.
105. PEDERSEN, L.M. & MILMAN, N. (1998). The prognostic value of thrombocytosis in patients with primary lung cancer]. Ugeskr. Laeger., 160, 3917-3920.
106. PHILIPPE, C., PHILIPPE, B., FOUQUERAY, B., PEREZ, J., LEBRET, M. & BAUD, L. (1993). Protection from tumor necrosis factor-mediated cytolysis by platelets. Am. J. Pathol., 143, 1713-1723.
107. PINEDO, H.M. & SLAMON, D.J. (2000). Introduction: translational research: the role of VEGF in tumor angiogenesis. Oncologist, 5, 1-2.
108. PINEDO, H.M., VERHEUL, H.M.W., D'AMATO, R.J. & FOLKMAN, J. (1998). Involvement of platelets in tumour angiogenesis? Lancet North. Am. Ed., 352, 1775-1777.
109. POTTRATZ, S.T., HALL, T.D., SCRIBNER, W.M., JAYARAM, H.N. & NATARAJAN, V. (1996). P-selectin-mediated attachment of small cell lung carcinoma to endothelial cells. Am. J. Physiol., 271, L918-L923.
110. RADOMSKI, A., JURASZ, P., SANDERS, E.J., OVERALL, C.M., BIGG, H.F., EDWARDS, D.R. & RADOMSKI, M.W. (2002). Identification, regulation and role of tissue inhibitor of metalloproteinases-4 (TIMP-4) in human platelets. Br. J. Pharmacol., 137, 1330-1338.
111. RADOMSKI, M.W., JENKINS, D.C., HOLMES, L. & MONCADA, S. (1991). Human colorectal adenocarcinoma cells: differential nitric oxide synthesis determines their ability to aggregate platelets. Cancer Res., 51, 6073-6078.
112. RADOMSKI, M.W. & MONCADA, S. (1993). Regulation of vascular homeostasis by nitric oxide. Thromb. Haemost., 70, 36-41.
113. RADOMSKI, M.W., PALMER, R.M. & MONCADA, S. (1987). The role of nitric oxide and cGMP in platelet adhesion to vascular endothelium. Biochem. Biophys. Res. Commun., 148, 1482-1489.
114. RADOMSKI, M.W. & RADOMSKI, A.S. (2000). Regulation of blood cell function by the endothelial cells. In: Vascular Endothelium in Human Physiology and Pathophysiology, ed Vallance, P.J.T. & Webb, D.J. London: Harwood Academic Publishers, pp. 95-106.
115. RICKLES, F.R. & FALANGA, A. (2001). Molecular basis for the relationship between thrombosis and cancer. Thromb. Res., 102, V215-V224.
116. RICKLES, F.R., LEVINE, M.N. & DVORAK, H.F. (2001). Abnormalities of hemostasis in malignancy. In: Hemostasis and Thrombosis Basic Principles and Clinical practice, ed Colman, R.F., Hirsh, J., Marder, V.J., Clowes, A.W. & George, J.N. Philadelphia: Lippincott Williams & Wilkins, pp. 1132-1152.
117. RICKLES, F.R., PATIERNO, S. & FERNANDEZ, P.M. (2003). Tissue factor, thrombin, and cancer. Chest, 124, 58S-68S.
118. SALGADO, R., BENOY, I., BOGERS, J., WEYTJENS, R., VERMEULEN, P., DIRIX, L. & VAN-MARCK, E. (2001). Platelets and vascular endothelial growth factor (VEGF): a morphological and functional study. Angiogenesis, 4, 37-43.
119. SANDLER, R.S., HALABI, S., BARON, J.A., BUDINGER, S., PASKETT, E., KERESZTES, R., PETRELLI, N., PIPAS, J.M., KARP, D.D., LOPRINZI, C.L., STEINBACH, G. & SCHILSKY, R. (2003). A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N. Engl. J. Med., 348, 883-890.
120. SAWICKI, G., SALAS, E., MURAT, J., MISZTA-LANE, H. & RADOMSKI, M.W. (1997). Release of gelatinase A during platelet activation mediates aggregation. Nature, 386, 616-619.
121. SCHINI-KERTH, V.B. (1999). Dual effects of insulin-like growth factor-I on the constitutive and inducible nitric oxide (NO) synthase-dependent formation of NO in vascular cells. J. Endocrinol. Invest., 22, 82-88.
122. SCHIRNER, M. & SCHNEIDER, M.R. (1992). The prostacyclin analogue cicaprost inhibits metastasis of tumours of R 3327 MAT Lu prostate carcinoma and SMT 2A mammary carcinoma. J. Cancer Res. Clin. Oncol, 118, 497-501.
123. SCHNEIDER, M.R., SCHILLINGER, E., SCHIRNER, M., SKUBALLA, W., STURZEBECHER, S. & WITT, W. (1991). Effects of prostacyclin analogues in in vivo tumor models. Adv. Prostaglandin Thromboxane Leukot. Res., 21B, 901-908.
124. SCHWARZ, U.R., WALTER, U. & EIGENTHALER, M. (2001). Taming platelets with cyclic nucleotides. Biochem. Pharmacol., 62, 1153-1161.
125. SHAU, H., ROTH, M.D. & GOLUB, S.H (1993). Regulation of natural killer function by nonlymphoid cells. Nat. Immun., 12, 235-249.
126. SPIGEL, S.C. & MOONEY, L.R. (1977). Extreme thrombocytosis associated with malignancy. Cancer, 39, 339-341.
127. STEINERT, B.W., TANG, D.G., GROSSI, I.M., UMBARGER, L.A. & HONN, K.V. (1993). Studies on the role of platelet eicosanoid metabolism and integrin alpha lib beta 3 in tumor-cell-induced platelet aggregation. Int. J. Cancer, 54, 92-101.
128. STONE, J.P. & WAGNER, D.D. (1993). P-selectin mediates adhesion of platelets to neuroblastoma and small cell lung cancer. J. Clin. Invest., 92, 804-813.
129. SUTHERLAND, D.E., WEITZ, I.C. & LIEBMAN, H.A. (2003). Thromboembolic complications of cancer: epidemiology, pathogenesis, diagnosis, and treatment. Am. J. Hematol., 72, 43-52.
130. TAUCHER, S., SALAT, A., GNANT, M., KWASNY, W., MLINERITSCH, B., MENZEL, R.C., SCHMID, M., SMOLA, M.G., STIERER, M., TAUSCH, C., GALID, A., STEGER, G. & JAKESZ, R. (2003). Impact of pretreatment thrombocytosis on survival in primary breast cancer. Thromb. Haemost., 89, 1098-1106.
131. TERRY, M.B., Gammon, M.D., ZHANG, F.F., TAWFIK, H., TEITELBAUM, S.L., BRITTON, J.A., SUBBARAMAIAH, K., DANNENBERG, A.J. & NEUGUT, A.I. (2004). Association of frequency and duration of aspirin use and hormone receptor status with breast cancer risk. JAMA, 291, 2433-2440.
132. 3 integrins in tumor growth, angiogenesis, and metastasis. Cancer Res., 62, 2824-2833.
133. TROUSSEAU, A. (1865). Phlegmasia alba dolens. In: Clinique Medicale de L'Hotel-Dieu Paris. London: New Sydenham Society, pp. 94-96.
134. TURITTO, V.T. & HALL, C.L. (1998). Mechanical factors affecting hemostasis and thrombosis. Thromb. Res., 92, S25-S31.
135. TZANAKAKIS, G.N., KRAMBOVITIS, E., TSATSAKIS, A.M. & VEZERIDIS, M.P. (2002). The preventive effect of ketoconazole on experimental metastasis from a human pancreatic carcinoma may be related to its effect on prostaglandin synthesis. Int. J. Gastrointest. Cancer, 32, 23-30.
136. VANE, J.R., BAKHLE, Y.S. & BOTTING, R.M. (1998). Cyclooxygenases 1 and 2. Annu. Rev. Pharmacol. Toxicol., 38, 97-120.
137. VARKI, A. & VARKI, N.M. (2001). P-selectin, carcinoma metastasis and heparin: novel mechanistic connections with therapeutic implications. Braz. J. Med. Biol. Res., 34, 711-717.
138. WAHRENBROCK, M., BORSIG, L., LE, D., VARKI, N. & VARKI, A. (2003). Selectin-mucin interactions as a probable molecular explanation for the association of Trousseau syndrome with mucinous adenocarcinomas. J. Clin. Invest., 112, 853-862.
139. WHITE, J.G. (1988). Platelet membrane ultrastructure and its changes during platelet activation. Prog. Clin. Biol. Res., 283, 1-32.
140. WHITE, R.H. (2003). The epidemiology of venous thromboembolism, Circulation, 107, 41-8.
141. ZACHARSKI, L.R. (2002). Anticoagulants in cancer treatment: malignancy as a solid phase coagulopathy. Cancer Lett., 186, 1-9.
142. ZACHARSKI, L.R., MEEHAN, K.R., ALGARRA, S.M. & CALVO, F.A. (1992). Clinical trials with anticoagulant and antiplatelet therapies. Cancer Metast. Rev., 11, 421-431.
143. ZACHARSKI, L.R., MEMOLI, V.A. & ROUSSEAU, S.M. (1986). Coagulation-cancer interaction in situ in renal cell carcinoma. Blood, 68, 394-399.
144. ZACHARSKI, L.R., MORITZ, T.E., BACZEK, L.A., RICKLES, F.R., EDWARDS, R.L., FORMAN, W.B., FORCIER, R.J., CORNELL, C.J., HAAKENSON, C.M., BALLARD, H.S., CRUM, E.D., JOHNSON, G.J., LEVINE, J., HONG, W.K., O'DONNELL, J.F., SCHILSKY, R.L., RINGENBERG, Q.S., ROBERT, F., SPAULDING, M.B., TORNYOS, K., WILLIAMS, C., ZUCKER, S., FAULKNER II, C.S., EATON, W.L. & HOPPEL, C.L. (1988). Effects of Mopidamol on survival in carcinoma of the lung and colon: final report of veterans administration cooperative study no. 188. J. Natl. Cancer Inst., 80, 90-97.
145. ZEIMET, A.C., MARTH, C., MULLER-HOLZNER, E., DAXENBICHLER, G. & DAPUNT, O. (1994). Significance of thrombocytosis in patients with epithelial ovarian cancer. Am. J. Obstet. Gynecol., 170, 549-554.